Accumulated evidence has shown that high expression of CD133 is associated with poor prognosis in several different types, including brain tumors, colorectal carcinoma, hepatoma, gastric carcinoma, and medulloblastoma.[11] Anti‐CD133 antibody‐conjugated immunotoxins inhibited the progression of cancer.[12] AC133‐specific CAR‐T cells recognized and killed patient‐derived GBM stem cells.[13] Thus, CD133 is considered as a new target for cancer therapy. Here, PROM1 is linked to gastric carcinoma.